Is it necessary to vaccinate immunodeficiency patients against influenza?


DOI: https://dx.doi.org/10.18565/therapy.2020.2.82-87

Latysheva T.V., Latysheva E.A., Setdikova N.Kh., Kostinova A.M.

State scientific Center «Institute of Immunology» of the Federal Medical and Biological Agency, Moscow
Vaccination is a leading measure in the prevention of infectious diseases. A decrease of the post-vaccine immune response is observed in immunocompromised patients, including patients with primary and secondary immunodeficiency. However, numerous studies have proved its effectiveness in this cohort of patients, leading to a decrease in complications, hospitalization, mortality and treatment costs. Fear of the development of complications after immunization, as well as low awareness of doctors in managing patients with immunodeficiency, significantly reduce the vaccination coverage of many groups of patients who need vaccination. The article gives a modern view of the immunization of immunocompromised patients, as well as actual data from recent studies on the formation of a post-vaccine immune response.
Keywords: immunocompromised, influenza vaccination, primary immunodeficiency, secondary immunodeficiency
Read entire article

Literature


  1. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009; 9(8): 493–504. doi: 10.1016/S1473-3099(09)70175-6.

  2. Zbinden D., Manuel O. Influenza vaccination in immunocompromised patients: efficacy and safety. Immunotherapy. 2014; 6(2): 131–39. doi: 10.2217/imt.13.171.

  3. Vandecasteele S.J., Ombelet S., Blumental S., Peetermans W.E. The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease. Clin Kidney J. 2015; 8(3): 318–24. doi: 10.1093/ckj/sfv030.

  4. Tomblyn M., Chiller T., Einsele H. et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15(10): 1143–238. doi: 10.1016/j.bbmt.2009.06.019.

  5. Al-Herz W., Bousfiha A., Casanova J.L. et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014; 5: 162. doi: 10.3389/fimmu.2014.00162.

  6. Chapel H., Prevot J., Gaspar H.B. et al. Primary immune deficiencies – principles of care. Front Immunol. 2014, 5; 627. doi: 10.3389/fimmu.2014.00627.

  7. Бембеева Р.Ц., Заваденко Н.Н. Внутривенные иммуноглобулины в терапии аутоиммунных заболеваний нервной системы у детей. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015; 115(8): 83–93. [Bembeeva R.Ts., Zavadenko N.N. Intravenous immunoglobulin in treatment of autoimmune neurological diseases in children. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015; 115(8): 83–93 (in Russ)]. doi: 10.17116/jnevro20151156183-93.

  8. Knipe D.M., Whelan S.P. Rethinking the response to emerging microbes: vaccines and therapeutics in the ebola era – a conference at Harvard Medical School. J Virol. 2015; 89(15): 7446–48. doi: 10.1128/JVI.01251-15.

  9. Mina M.J., Metcalf C.J., de Swart R.L. et al. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015; 348(6235): 694–99. doi: 10.1126/science.aaa3662.

  10. Infant meningococcal vaccination: advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep. 2013; 62(3), 52–54.

  11. Grohskopf L.A., Olsen S.J., Sokolow L.Z. et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) – United States, 2014–2015 influenza season. MMWR Morb Mortal Wkly Rep. 2014; 63(32): 691–97.

  12. Markowitz L.E., Dunne E.F., Saraiya M. et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014; 63(RR–05): 1–30.

  13. Bridges C.B., Coyne-Beasley T. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older – United States, 2014. MMWR Morb Mortal Wkly Rep. 2014; 63(5): 110–12.

  14. Grohskopf L.A., Shay D.K., Shimabukuro T.T. et al. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices – United States, 2013–2014. MMWR Recomm Rep. 2013;62(RR–07): 1–43.

  15. Strikas R.A. Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years – United States, 2015. MMWR Morb Mortal. Wkly Rep. 2015; 64(4): 93–94.

  16. Kim D.K., Bridges C.B., Harriman K.H. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older – United States, 2015. MMWR Morb Mortal Wkly Rep. 2015; 64(4): 91–92.

  17. Urun Y., Akbulut H., Demirkazik A. et al. Perception about influenza and pneumococcal vaccines and vaccination coverage among patients with malignancies and their family members. J BUON. 2013; 18(2); 511–15.

  18. Morrill H.J., Caffrey A.R., Noh E., LaPlante K.L. Epidemiology of pneumococcal disease in a national cohort of older adults. Infect. Dis. Ther. 2014; 3(1): 19–33. doi: 10.1007/s40121-014-0025-y.

  19. Vinograd I., Baslo R., Eliakim-Raz N. et al. Factors associated with influenza vaccination among adult cancer patients: a case–control study. Clin Microbiol Infect. 2014; 20(9): 899–905. doi: 10.1111/1469-0691.12625.

  20. Cesaro S., Giacchino M., Fioredda F. et al. Guidelines on vaccinations in paediatric haematology and oncology patients. Biomed Res Int. 2014; 2014: 707691. doi: 10.1155/2014/707691.

  21. Principi N., Esposito S. Vaccine use in primary immunodeficiency disorders. Vaccine. 2014; 32(30): 3725–31. doi: 10.1016/j.vaccine.2014.05.022.

  22. Rubin L.G., Levin M.J., Ljungman P. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58(3): 309–18. doi: 10.1093/cid/cit816.

  23. Centers for Disease Control and Prevention. In: Epidemiology and Prevention of Vaccine-Preventable Diseases (13th Edition). Hamborsky J, Kroger A, Wolfe S (Eds). Public Health Foundation, Washington DC. 2015.

  24. American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care. 2014; 37(Suppl. 1): S14–S80. doi: 10.2337/dc14-S014.

  25. Чучалин А.Г., Биличенко Т.И., Осипова Г.Л. с соавт. Вакцинопрофилактика болезней органов дыхания в рамках первичной медико-санитарной помощи населению. Клинические рекомендации. Пульмонология. Приложение. 2015; 2(25): 1–19. [Chuchalin A.G., Bilichenko T.I., Osipova G.L. et al. Vaccine-based prevention of diseases of the respiratory system as part of the outpatient medical assistance for population. Pul'monologiya. 2015; 2(25): 1–19 (In Russ.)].

  26. Вакцинация детей с нарушенным состоянием здоровья. Практическое руководство для врачей. 4-е изд. Под. ред. М.П. Костинова. М.: Медицина для всех, 2013; 432 с. [Vaccination of children with health disorders. Practical guide for physicians. 4th Issue. Edited by Kostinov M.P. M.: Meditsina dlya vseh. 2013; 432 p. (In Russ.)].

  27. Gardulf А., Abolhassani Н., Gustafson R. et al. Predictive markers for humoral influenza vaccine response in patients with common variable immunodeficiency (CVID). J Allergy Clin Immunol. 2018; 142(6): 1922–31.e2. doi: 10.1016/j.jaci.2018.02.052.

  28. Hanitsch L.G., Lobel M., Mieves J.F. et al. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency. Vaccine. 2016; 34(21): 2417–23. doi: 10.1016/j.vaccine.2016.03.091.

  29. Хромова Е.А., Семочкин И.А., Ахматова Э.А. с соавт. Вакцины против гриппа: влияние на TLRs. Российский иммунологический журнал. 2016; 10(2-1): 505–507. [Khromova E.A., Semochkin A.A., Akhmatova E.A. et al. Influenza vaccines: influence on TLRs expression. Rossiyskiy immunologicheskiy zhurnal. 2016; 10(2-1): 505–507 (In Russ.)].

  30. Хромова Е.А., Семочкин И.А., Ахматова Э.А. с соавт. Изменение иммунофенотипа лимфоцитов под влиянием иммуноадъювантных и безадъювантных вакцин против гриппа. Российский иммунологический журнал. 2016; 10(2-1): 503–504. [Khromova E.A., Semochkin A.A., Akhmatova E.A. et al. Change of lymphocytes immunophenotype under the influence of the adjuvanted and non-adjuvanted anti-influenza vaccines. Rossiyskiy immunologicheskiy zhurnal. 2016; 10(2-1):503–504(In Russ.)].

  31. Хромова Е.Е., Семочкин И.А., Ахматова Э.А. с соавт. Сравнительная активность вакцин против гриппа: влияние на субпопуляционную структуру лимфоцитов. Журнал микробиологии, эпидемиологии и иммунобиологии. 2016; 6: 61–65. [Khromova E.A., Semochkin A.A., Akhmatova E.A. et al. Comparative activity of influenza vaccines: effect on lymphocyte subpopulation structure. Zhurnal microbiologii, epidemiologii i immunobiologii. 2016; 6: 61–65 (In Russ.)].

  32. Kostinov M.P., Akhmatova N.K., Khromova E.A. et al. The impact of adjuvanted and non-adjuvanted influenza vaccines on the innate and adaptive immunity effectors. IntechOpen book series. Infectious diseases, volume 1. Influenza. Therapeutics and challenges. Edited by Shailendra K. Saxena 2018. Chapter 5. РP. 83–109.

  33. Руководство по клинической иммунологии в респираторной медицине (2-е изд. допол.). Под ред. М.П. Костинова, А.Г. Чучалина. М.: Группа МДВ, 2018; 304 с. [Practical guide on clinical immunology in respiratory medicine (2nd Issue). Edited by Kostinov M.P., Chuchalin A.G. M.: MDV Group. 2018; 304 p. (In Russ.)].

  34. Об осложнениях гриппа. Почему необходимо обращаться к врачу? ФБУЗ «Центр гигиенического образования населения» Роспотребнадзора. 2019. [About complications of influenza. Why is it necessary to see a doctor? Center of hygiene education of the population of Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing. 2019 (In Russ.)].

  35. Руководство по клинической иммунологии в респираторной медицине (1-е изд.). Под ред. М.П. Костинова, А.Г. Чучалина. М.: ООО АТМО. 2016: 128. [Guide on clinical immunology in respiratory medicine (1st Issue). Edited by Kostinov M.P., Chuchalin A.G. M.: ATMO LLC. 2016: 128 (In Russ.)].

  36. Flu vaccination сoverage, United States, 2018–19 Influenza Season. FluVaxView webpage report posted online September 26, 2019.

  37. Hughes M.M., Reed C., Flannery B. et al. Projected population benefit of increased effectiveness and coverage of influenza vaccination on influenza burden – United States. Clin Infect Dis. 2019. pii: ciz676. doi: 10.1093/cid/ciz676.

  38. Wumkes M.L., van der Velden A.M., Los M. et al. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine. 2013; 31(52): 6177–84. doi: 10.1016/j.vaccine.2013.10.053.

  39. Shehata M.A., Karim N.A. Influenza vaccination in cancer patients undergoing systemic therapy. Clin Med Insights Oncol. 2014; 8, 57–64. doi: 10.4137/CMO.S13774.

  40. Aikawa N.E., Trudes G., Campos L.M. et al. Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients. Lupus. 2013; 22(13): 1394–98. doi: 10.1177/0961203313505926.

  41. Beck C.R., McKenzie B.C., Hashim A.B. et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS ONE. 2011; 6(12), e29249. doi: 10.1371/journal.pone.0029249.

  42. Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. Руководство для врачей. М.: МДВ. 2009; 252. [Kostinov M.P., Tarasova A.A. Vaccine-based prevention of pneumococcal infection in autoimmune diseases. Practical guide for physicians. M.: MDV. 2009; 252 (In Russ.)].


About the Autors

Tatyana V. Latysheva, MD, professor, professor of the Department of clinical allergology and immunology of the faculty of continuing professional education of A.I. Evdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia, head of the Department of immunopathology and intensive care of clinic of SSC Institute of immunology of FMBA of Russia, anesthetist-resuscitator of the highest category, Honored doctor of Russia. Address: 115478, Moscow, 24 Kashirskoye Shosse Str. Tel.: +7 (499) 617-80-85. E-mail: tv.latysheva@nrcii.ru
Elena A. Latysheva, MD, associate professor of the Department of Clinical immunology of the faculty of MBF of N.I. Pirogov Russian National research medical University of the Ministry of Healthcare of Russia, senior researcher of the Department of immunopathology, clinic of the SSC Institute of immunology of FMBA of Russia.
Address: 115478, Moscow, 24 Kashirskoye Shosse Str. Tel.: +7 (499) 612-77-73. E-mail: ea.latysheva@nrcii.ru
Naila Kh. Setdikova, MD, associate professor of the Department of clinical allergology and immunology of the faculty of continuing professional education of A.I. Evdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia, leading researcher of the Department of immunopathology of Clinic of SSC Institute of immunology of FMBA of Russia, allergist-immunologist of the highest category. Address: 115478, Moscow, 24 Kashirskoye Shosse Str. Tel.: +7 (499) 612-88-29. E-mail: nh.setdikova@nrcii.ru
Aristitsa M. Kostinova, postgraduate student of the Department of immunopathology of Clinic of SSC Institute of Immunology FMBA of Russia. 115478, Moscow, 24 Kashirskoye Shosse Str. Tel.: +7 (499) 612-88-29. E-mail: aristica_kostino@mail.ru


Similar Articles

Back to Content

Бионика Медиа